R
heumatoid arthritis is one of the commonest autoimmune diseases, with a prevalence of about 1%, and it is perhaps the most common reversible disability in the Western world. After 10 years, 50% of people with rheumatoid arthritis in employment no longer work, most losing their jobs in the first 12 months after diagnosis. 1 Excessive amounts of the pro-inflammatory cytokines, tumour necrosis factor, TNF interleukin-1 (IL-1 ), and interleukin-6 (IL-6), mediate most of the pathogenic features of rheumatoid arthritis. Infliximab, the chimeric antibody to tumour necrosis factor , and etanercept, a fusion protein p75 tumour necrosis factor receptor immunoglobulin, have been shown to be very effective in reducing the chronic symptoms and signs of rheumatoid arthritis in patients who fail to respond to conventional treatment with disease modifying drugs.
2 Both these molecules produce response rates which are at least as high as those seen with other treatments given for milder disease. Importantly, these drugs have been shown to be effective in patients who were thought to be resistant to all treatment. Before these new drugs such patients were left to deteriorate, resulting in cachexic individuals with destroyed joints, a picture all too familiar to physicians.
Most physicians believed that because of the redundancy of the overlapping actions of the pro-inflammatory cytokines, blockade of a single cytokine would be insufficient to control the disease. 3 Experimental evidence, however, suggests a hierarchy of cytokines, and a phase II study of infliximab, which is a chimeric mouse-human antitumour necrosis factor molecular antibody, showed that blockade could be effective. 4 The downside was tachyphylaxis on repeated infusions, which meant long term treatment would not be possible. Giving methotrexate concurrently, however, suppressed tachyphylaxis, probably by preventing the production of human antichimeric antibodies. 5 Though tumour necrosis factor blockade was expected to have a major impact on inflammatory symptoms, we did not know whether it would influence bony disease, where evidence suggested that IL-1 was a major mediator.
6 Surprisingly, radiological damage showed more improvement than did clinical symptoms, particularly with infliximab. Radiological progression over a one and two year period was effectively abolished. 7 The drugs were licensed in the European Union over 18 months ago: infliximab to be given intravenously with methotrexate at intervals of eight weeks after an induction period, and etanercept given subcutaneously twice a week either as monotherapy or with methotrexate. At registration their known toxicities were the rare induction of autoantibodiesparticularly antinuclear antibodies and double stranded deoxyribonucleic acid antibodies, reversible systemic lupus erythematosus, a slight increase in upper respiratory tract infections, and minor problems in giving the drugs such as infusion and injection site reactions. In addition, there were concerns about an increase in rates of malignancy.
Since registration around 300 000 patients have been treated worldwide with these agents. Most are in the United States, where health maintenance organisations have reimbursed treatment, and the licensing authorities have accepted the data on radiological and clinical improvement. An increased risk of malignancy has not been confirmed, but there have been other problems like reactivation of mycobacterial infection on infliximab, worsening of demyelinating disease, suppression of bone marrow on etanercept, and a variety of unusual idiosyncratic side effects. Patients at increased risk of sepsis, for example those on high doses of steroids or with poorly controlled diabetes, are excluded from treatment. In clinical practice these drugs have been as effective as in controlled clinical trials, but these are complex drugs with major effects on the immune system and they need close monitoring. At present they remain drugs to be used in secondary care by experienced physicians.
The most difficult question is: at what stage of the disease do we use these drugs? In the United States they are becoming first line therapy, whereas in Europe they are used only after one or two disease modifying drugs have failed. Guidelines have been issued for their use. [8] [9] [10] Etanercept has been compared with methotrexate in early disease and shown benefits but probably insufficient to recommend unlimited use. 11 The availability of these agents has encouraged better use of existing disease modifying drugs and at a higher dose. This in turn has reduced the cost effectiveness of the non-selective use of tumour necrosis factor therapy.
Guidelines for their use in the United Kingdom are expected by March 2002 from the National Institute for Clinical Excellence. Meanwhile, health authorities have had to make money available on an ad hoc basis. Optimal treatment for an important disease is being determined by arbitrary factors, such as a person's address ("postcode prescribing"). A recent review suggests that up to 50% of people with rheumatoid arthritis in the United Kingdom do not have access to these drugs. Yet there is wide agreement, aided by the realisation of the severe side effects of untreated active disease, that these drugs are cost effective in patients who have failed to respond to an adequate trial of conventional drugs. 12 Tumour necrosis factor blockade costs about £6000-£8000 ($9000-$12 000) a year per patient. In countries with limited budgets this has necessitated targeting treatment to appropriate patients and prompted a realisation that it should not be continued in the 25% of patients who do not respond. The non-response may be due to the heterogeneity of disease with genetic factors, dominant cytokines, and currently used doses. The imminent availability of blockade of IL-1 via the use of an IL-1 receptor antagonist (anakrina) and the evidence that combined blockade of both tumour necrosis factor and IL-1 is very effective in animal models will stimulate further research. Present evidence suggests that blockade of tumour necrosis factor , though effective, does not cure and that permanent treatment is needed. The positive side is that these drugs have confirmed that the underlying disease of rheumatoid arthritis is treatable. The absence of a cure has also stimulated more research for agents capable of long term immunomodulation.
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Quality of economic evaluations in health care
It is time for action to ensure higher methodological quality E conomic evaluation is becoming established globally as one of the tools for decision making in health care.
1 Its rise in popularity is reflected by the increasing number of published economic evaluations. One source estimates that 1803 economic evaluations were published in medical journals in 1979-90, 2 rising to 2222 in 1991-6. 3 This increase in both the availability of economic evaluations and willingness to use their results to allocate scarce resources reinforces the need for evaluations to be methodologically sound so that the consequent healthcare decisions are ethically defensible. Do our current economic evaluations meet the necessary methodological requirements?
In the early 1990s several systematic reviews cast doubt on the scientific reliability of some published evaluations. All advocated better standards of conducting and reporting economic evaluations. [4] [5] [6] [7] A subsequent survey among editors of medical journals found that none had a coherent editorial policy for economic evaluations, and few had peer reviewers with knowledge of health economics. 8 Thus one of the quality control mechanisms of the research community, peer review, was failing to ensure adequate methodological standards.
Following interest by researchers and editors, the BMJ defined and promulgated guidelines for editors and peer reviewers aimed at ensuring clear standards for both submission and editorial management of economic evaluations. 9 The impact of the guidelines was evaluated shortly after their publication, but they have since been used only in editorial management. 10 The BMJ guidelines came at a time of similar initiatives to address poor methodology in the reporting of studies, such as the CONSORT statement on randomised controlled trials and, later, the QUORUM statement on systematic reviews. While preliminary indications are that the use of CONSORT is effective in improving the quality of reports of randomised controlled trials, 11 12 the effect of the BMJ and other guidelines on the quality of economic evaluations appears muted.
Several important economic methodological reviews have been published in the 1990s. Although coverage of economic evaluation has been limited and the tools used for quality assessment have varied, the overall conclusions show that there is a long way to go before economic evaluations can be regarded as good enough to justify their use in decision making.
For example, in an assessment of 228 cost utility analyses over the period 1976-97 Neumann et al found wide variations in quality of reporting, a modest improvement over time, and a tendency for better reporting in general medical journals than in specialist journals. 13 In a similar assessment Gerard et al showed
